John Murphy, CEO, The COVID-19 Long-haul Foundation<\/p>\n\n\n\n
Review Article<\/strong><\/p>\n\n\n\n Long Covid, or post\u2013COVID-19 condition, has emerged as a heterogeneous, multisystem disorder that may persist for months or years after acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Among its most consequential neuropsychiatric manifestations is depression. Depression in the setting of Long Covid occupies an unusual position in contemporary medicine: it may represent a primary psychiatric disorder precipitated by the experience of chronic illness and disability, a neuropsychiatric consequence of SARS-CoV-2 infection, a manifestation of systemic inflammation and altered immune signaling, or some combination of these processes. The distinction is clinically important but often difficult to establish.<\/p>\n\n\n\n The available evidence indicates that depressive symptoms are substantially more common among persons with Long Covid than in many comparable populations. A 2024 systematic review and meta-analysis estimated a pooled prevalence of depression of approximately 23% among persons with post\u2013COVID-19 syndrome, although heterogeneity among studies was extreme. A subsequent 2025 meta-analysis estimated depression in approximately 25% of persons with Long Covid, again with very wide prediction intervals, reflecting substantial differences in populations, definitions, instruments, and follow-up intervals.<\/p>\n\n\n\n Several mechanisms may contribute. These include persistent immune activation, endothelial and microvascular dysfunction, autonomic disturbance, altered tryptophan\u2013kynurenine metabolism, hypothalamic\u2013pituitary\u2013adrenal-axis abnormalities, mitochondrial dysfunction, sleep disruption, dysautonomia, persistent viral antigen or viral reservoirs, autoimmunity, and direct or indirect effects on the central nervous system. None, however, provides a complete explanation for all cases. Current evidence favors a model of biological heterogeneity rather than a single pathophysiologic pathway.<\/p>\n\n\n\n Diagnosis requires a comprehensive psychiatric and medical assessment. Clinicians must distinguish major depressive disorder from demoralization, adjustment disorder, post-traumatic stress disorder, anxiety, sleep disorders, cognitive dysfunction, fatigue associated with Long Covid, medication effects, endocrine disease, anemia, metabolic disease, neurologic disorders, substance use, and other medical causes. Particular attention must be given to suicidal ideation, psychosis, mania, catatonia, and rapidly progressive cognitive or functional deterioration.<\/p>\n\n\n\n Treatment should not be reduced to either “treating depression” or “treating Long Covid.” Optimal care is multidimensional and individualized. Evidence-based treatment of depression \u2014 including psychotherapy, antidepressant medication when appropriate, and electroconvulsive or other advanced treatments for selected severe cases \u2014 should proceed alongside management of the underlying Long Covid phenotype, sleep disorders, autonomic dysfunction, pain, post-exertional malaise, cognitive impairment, and other medical contributors. No pharmacologic therapy has yet been established as a disease-modifying treatment specifically for Long Covid\u2013associated depression. Current Long Covid guidance emphasizes symptom-directed care, functional rehabilitation, management of coexisting conditions, and patient-centered longitudinal follow-up.<\/p>\n\n\n\n The prognosis is variable. Some patients experience substantial improvement, whereas others have persistent or relapsing symptoms over several years. Depression may amplify disability, cognitive complaints, sleep disturbance, pain, social withdrawal, and loss of occupational or functional capacity, potentially creating a self-reinforcing cycle of biological and psychosocial illness. Recognition and treatment of depression should therefore be regarded not as ancillary psychiatric care but as an integral component of Long Covid management.<\/p>\n\n\n\n The history of medicine contains numerous examples of illnesses initially understood through the anatomy of a single organ and subsequently recognized as disorders of interconnected physiologic systems. Long Covid belongs unmistakably to the latter category.<\/p>\n\n\n\n SARS-CoV-2 first appeared to produce a predominantly respiratory illness. Yet as the pandemic progressed, it became evident that recovery from the acute infection did not invariably represent restoration of physiologic normality. Patients described persistent fatigue, exertional intolerance, dyspnea, tachycardia, orthostatic symptoms, sleep disturbance, anosmia, dysgeusia, neuropathic symptoms, cognitive dysfunction, headache, gastrointestinal abnormalities, pain, and affective disturbances. Symptoms could persist continuously, appear after an interval of apparent recovery, disappear and recur, or evolve into entirely different clinical syndromes. The World Health Organization consequently established a clinical definition of post\u2013COVID-19 condition encompassing persistent or newly developed symptoms occurring generally three months after the initial infection and lasting at least two months without another explanation.<\/p>\n\n\n\n The Centers for Disease Control and Prevention now characterizes Long Covid as an infection-associated chronic condition affecting one or more organ systems. Its current clinical guidance emphasizes that Long Covid can be continuous, relapsing and remitting, or progressive; that no single laboratory test establishes or excludes the diagnosis; and that treatment should be individualized according to the patient’s most burdensome symptoms and associated conditions.<\/p>\n\n\n\n Depression occupies a particularly important position within this syndrome.<\/p>\n\n\n\n The importance is not simply epidemiologic. Depression can alter the patient’s perception of symptoms, motivation, sleep, cognition, social engagement, adherence to treatment, physical activity, and capacity for rehabilitation. Conversely, persistent physical disability, pain, cognitive dysfunction, loss of employment, financial insecurity, social isolation, and uncertainty about recovery can produce profound psychological distress. The relationship therefore is bidirectional.<\/p>\n\n\n\n The central clinical error is to assume that one explanation excludes the other.<\/p>\n\n\n\n A patient with Long Covid may simultaneously have biologically mediated neurologic dysfunction and major depressive disorder. Another patient may have predominantly autonomic dysfunction with secondary demoralization. A third may have major depressive disorder unrelated to SARS-CoV-2 that happened to emerge after infection. A fourth may have inflammatory or metabolic disease masquerading as depression. These distinctions require careful clinical reasoning rather than categorical assumptions.<\/p>\n\n\n\n The terminology has evolved. “Long Covid,” “post\u2013COVID-19 condition,” “post-COVID syndrome,” and “post-acute sequelae of SARS-CoV-2 infection” have all been used. The terminology is imperfect because the syndrome encompasses multiple phenotypes rather than a single disease entity.<\/p>\n\n\n\n WHO estimates have varied according to methodology and population. WHO currently reports that approximately 6% of people who have had Covid-19 develop post\u2013COVID-19 condition, while earlier estimates placed the proportion substantially higher. The CDC emphasizes that symptoms can persist for months or years and may emerge, disappear, and recur.<\/p>\n\n\n\n This variability is not merely statistical noise. It reflects a fundamental problem: Long Covid is a syndrome produced by multiple possible biological pathways.<\/p>\n\n\n\n Depression is similarly heterogeneous.<\/p>\n\n\n\n The term may refer to:<\/p>\n\n\n\n The distinction is crucial because the treatment and prognosis differ.<\/p>\n\n\n\n The diagnosis of major depressive disorder should not be made simply because a patient with Long Covid reports sadness, fatigue, impaired concentration, or reduced activity. Many of these symptoms overlap directly with Long Covid itself.<\/p>\n\n\n\n Depressive symptoms were recognized early during the pandemic, but the psychiatric burden associated specifically with persistent postinfectious illness has become increasingly apparent.<\/p>\n\n\n\n A 2024 systematic review and meta-analysis incorporating 143 studies and more than 7.7 million participants estimated a pooled depression prevalence of approximately 23% among persons with Long Covid. The enormous heterogeneity (I\u00b2 approximately 99.9%) is itself an important finding: prevalence estimates differ substantially according to the population studied, definition of Long Covid, timing of assessment, and depression instrument used.<\/p>\n\n\n\n A 2025 systematic review and meta-analysis of 94 studies estimated the prevalence of depression at approximately 25%, with a 95% confidence interval of 22 to 28%. The investigators also found substantial prevalence of anxiety, stress, and suicidality, although estimates again varied considerably across studies.<\/p>\n\n\n\n Earlier meta-analysis of neuropsychiatric manifestations after Covid-19 estimated depression in approximately 12% of patients followed at least three months after infection.<\/p>\n\n\n\n These numbers should not be interpreted as a precise population prevalence.<\/p>\n\n\n\n There are several reasons.<\/p>\n\n\n\n First, many studies use screening instruments rather than structured psychiatric interviews. A high score on the Patient Health Questionnaire-9 (PHQ-9), for example, does not necessarily establish major depressive disorder.<\/p>\n\n\n\n Second, somatic symptoms of Long Covid \u2014 particularly fatigue, sleep disturbance, psychomotor slowing, and impaired concentration \u2014 can inflate depression scores.<\/p>\n\n\n\n Third, studies differ in whether they enroll hospitalized patients, community cases, patients attending specialized Long Covid clinics, or self-selected online cohorts.<\/p>\n\n\n\n Fourth, disease severity and vaccination status have changed across pandemic eras.<\/p>\n\n\n\n Fifth, ascertainment bias is unavoidable in many specialty-clinic populations.<\/p>\n\n\n\n Thus, the most defensible conclusion is not that exactly one quarter of patients with Long Covid have major depressive disorder. Rather, clinically important depressive symptoms are common, substantially more common than would be acceptable to ignore, and present across diverse Long Covid populations.<\/strong><\/p>\n\n\n\n The etiologic model should be multidimensional.<\/p>\n\n\n\n A useful conceptual framework contains six overlapping pathways:<\/p>\n\n\n\n These pathways are not mutually exclusive.<\/p>\n\n\n\n Indeed, their interaction may explain the clinical diversity of Long Covid.<\/p>\n\n\n\n Inflammation has long been implicated in depression.<\/p>\n\n\n\n The classical monoamine model of depression \u2014 centered on serotonin, norepinephrine, and dopamine \u2014 remains clinically useful but is biologically incomplete. Contemporary models incorporate neuroimmune signaling, synaptic plasticity, glutamatergic transmission, neuroendocrine regulation, mitochondrial function, and network-level changes.<\/p>\n\n\n\n SARS-CoV-2 infection provides multiple potential routes by which immune activation might influence brain function.<\/p>\n\n\n\n Peripheral inflammatory mediators can affect the central nervous system through several mechanisms:<\/p>\n\n\n\n Microglial activation is particularly important conceptually.<\/p>\n\n\n\n Microglia are the resident immune cells of the central nervous system. Their activation can alter synaptic function and produce inflammatory mediators that influence neuronal excitability, energy metabolism, and neuroplasticity.<\/p>\n\n\n\n Whether persistent microglial activation is a primary driver of depression in Long Covid remains unresolved. Nevertheless, it provides a biologically plausible bridge between infection, systemic inflammation, cognitive dysfunction, fatigue, sleep abnormalities, and affective symptoms.<\/p>\n\n\n\n The important point is one of probability rather than proof.<\/p>\n\n\n\n It is reasonable to regard neuroinflammation as one candidate mechanism.<\/p>\n\n\n\n It is not reasonable to state that neuroinflammation has been established as the singular cause of Long Covid\u2013associated depression.<\/p>\n\n\n\n One particularly interesting pathway involves tryptophan metabolism.<\/p>\n\n\n\n Inflammatory signaling can alter the metabolism of tryptophan through the kynurenine pathway. Because tryptophan is also the precursor for serotonin, immune-mediated changes in substrate availability and metabolic routing have been proposed as one mechanism linking systemic inflammation to affective and cognitive symptoms.<\/p>\n\n\n\n The kynurenine pathway also generates metabolites capable of influencing glutamatergic neurotransmission and neuronal function.<\/p>\n\n\n\n This model is attractive because it potentially connects several observations:<\/p>\n\n\n\n infection \u2192 immune activation \u2192 altered tryptophan metabolism \u2192 altered neurotransmitter biology \u2192 cognitive and affective symptoms.<\/strong><\/p>\n\n\n\n But the pathway should not be overinterpreted.<\/p>\n\n\n\n Depression is not simply “low serotonin,” and contemporary psychiatric neuroscience does not support reducing major depression to a single neurotransmitter deficiency. Contemporary literature continues to debate the precise contribution of serotonergic mechanisms to depression.<\/p>\n\n\n\n Antidepressant efficacy, furthermore, cannot be used as proof of a particular biochemical etiology.<\/p>\n\n\n\n Long Covid has generated substantial interest in endothelial injury and microvascular dysfunction.<\/p>\n\n\n\n The endothelium regulates vascular tone, coagulation, permeability, inflammation, and tissue perfusion. SARS-CoV-2 infection can produce profound systemic endothelial stress during acute disease, and persistent vascular abnormalities have been proposed in subsets of patients with Long Covid.<\/p>\n\n\n\n If cerebral microvascular function is impaired, several downstream consequences could theoretically occur:<\/p>\n\n\n\n Such mechanisms could contribute to cognitive dysfunction, headache, fatigue, and potentially mood disturbance.<\/p>\n\n\n\n Nevertheless, evidence linking a specific microvascular lesion to depression in an individual Long Covid patient remains insufficient.<\/p>\n\n\n\n This distinction matters clinically.<\/p>\n\n\n\n The discovery of a plausible population-level mechanism does not establish that the mechanism is operating in every individual patient.<\/p>\n\n\n\n One of the most important unresolved questions in Long Covid is whether SARS-CoV-2 or viral components persist in tissues after the acute infection.<\/p>\n\n\n\n Several studies have identified viral RNA, proteins, or antigenic material in tissues or biological compartments after acute infection. Whether such findings represent replication-competent virus, residual antigen, or immunologically relevant debris remains incompletely resolved.<\/p>\n\n\n\n If persistent antigenic stimulation occurs, it could theoretically maintain:<\/p>\n\n\n\n The CDC explicitly recognizes ongoing viral activity associated with an intra-host viral reservoir as one of several proposed Long Covid mechanisms, alongside organ damage, dysregulated inflammation, microvascular dysfunction, and autoimmunity.<\/p>\n\n\n\n The word possible<\/strong> is important.<\/p>\n\n\n\n Persistent viral reservoirs are a compelling hypothesis, but they cannot currently be invoked as a universal explanation for Long Covid depression.<\/p>\n\n\n\n SARS-CoV-2 infection can disturb immune tolerance.<\/p>\n\n\n\n Autoantibodies have been detected in subsets of patients after infection, and autoimmune phenomena have been proposed as contributors to Long Covid.<\/p>\n\n\n\n Potential mechanisms include:<\/p>\n\n\n\n Autoimmunity could theoretically affect the nervous system directly or indirectly.<\/p>\n\n\n\n However, the presence of an autoantibody does not establish pathogenic autoimmunity.<\/p>\n\n\n\n This is particularly important in patients with psychiatric symptoms because the temptation to construct an immunologic explanation can exceed the available evidence.<\/p>\n\n\n\n Autonomic dysfunction is increasingly recognized in Long Covid.<\/p>\n\n\n\n Patients may report:<\/p>\n\n\n\n Postural orthostatic tachycardia syndrome and related dysautonomias can be extraordinarily disabling.<\/p>\n\n\n\n The resulting disability may itself precipitate depression.<\/p>\n\n\n\n More importantly, autonomic dysfunction can produce symptoms that resemble anxiety or panic:<\/p>\n\n\n\n Mislabeling these manifestations as psychiatric symptoms can delay appropriate diagnosis.<\/p>\n\n\n\n Conversely, anxiety and depression can amplify autonomic symptoms.<\/p>\n\n\n\n Thus, the relationship is bidirectional.<\/p>\n\n\n\n Persistent fatigue is among the most characteristic symptoms of Long Covid.<\/p>\n\n\n\n Mitochondria are central to cellular energy production. Several investigations have reported metabolic abnormalities after SARS-CoV-2 infection, including disturbances involving mitochondrial function, oxidative stress, lipid metabolism, and energy utilization.<\/p>\n\n\n\n The hypothesis is particularly attractive in patients with:<\/p>\n\n\n\n Yet mitochondrial dysfunction is not synonymous with depression.<\/p>\n\n\n\n A patient may have mitochondrial or metabolic abnormalities and no depressive illness.<\/p>\n\n\n\n Conversely, a depressed patient may have normal mitochondrial physiology.<\/p>\n\n\n\n The two conditions may coexist without one being the cause of the other.<\/p>\n\n\n\n The hypothalamic\u2013pituitary\u2013adrenal (HPA) axis is involved in the regulation of stress, metabolism, immune function, and mood.<\/p>\n\n\n\n COVID-19 and prolonged illness can disturb endocrine physiology. Altered cortisol dynamics have been described in subsets of patients with persistent postinfectious symptoms.<\/p>\n\n\n\n Because the HPA axis is also implicated in depression, it provides another potential intersection between Long Covid and affective illness.<\/p>\n\n\n\n The clinical implications remain uncertain.<\/p>\n\n\n\n Routine cortisol testing is not a diagnostic test for Long Covid depression.<\/p>\n\n\n\n Testing should instead be guided by clinical suspicion of endocrine disease, such as adrenal insufficiency or Cushing’s syndrome.<\/p>\n\n\n\n Sleep disturbance deserves special emphasis.<\/p>\n\n\n\n Patients with Long Covid commonly report:<\/p>\n\n\n\n Sleep disturbance can independently cause:<\/p>\n\n\n\n Conversely, depression can worsen sleep.<\/p>\n\n\n\n The resulting feedback loop may become self-sustaining:<\/p>\n\n\n\n Long Covid \u2192 poor sleep \u2192 fatigue and cognitive dysfunction \u2192 reduced activity \u2192 depressed mood \u2192 worse sleep \u2192 greater disability.<\/strong><\/p>\n\n\n\n For this reason, sleep assessment should be a routine component of evaluation.<\/p>\n\n\n\n Pain is one of the strongest clinical bridges between Long Covid and depression.<\/p>\n\n\n\n Persistent neuropathic, musculoskeletal, headache, abdominal, or generalized pain can alter:<\/p>\n\n\n\n Pain and depression also share neurobiologic pathways involving inflammatory mediators, descending pain modulation, monoaminergic transmission, and central sensitization.<\/p>\n\n\n\n The patient may therefore enter a vicious cycle:<\/p>\n\n\n\n pain \u2192 insomnia \u2192 fatigue \u2192 inactivity \u2192 social isolation \u2192 depression \u2192 amplified pain.<\/strong><\/p>\n\n\n\n Treatment that addresses only mood while ignoring pain is often inadequate.<\/p>\n\n\n\n Biology alone cannot explain all depression in Long Covid.<\/p>\n\n\n\n Chronic illness can radically alter a person’s identity.<\/p>\n\n\n\n An individual who was previously employed may become unable to work. A physically active person may become exercise-intolerant. A caregiver may become dependent on others. Someone who previously managed finances, transportation, household responsibilities, and social relationships may suddenly require assistance.<\/p>\n\n\n\n These changes are psychologically consequential.<\/p>\n\n\n\n The patient may grieve:<\/p>\n\n\n\n Such grief is not evidence that the illness is psychological.<\/p>\n\n\n\n Nor does the existence of a biological disease protect against ordinary psychological responses to disability.<\/p>\n\n\n\n The best clinical model is therefore neither “the illness is all in the brain” nor “the illness is entirely biological.”<\/p>\n\n\n\n It is biopsychosocial in the strongest scientific sense: biological, psychological, and social mechanisms interact.<\/p>\n\n\n\n Depression associated with Long Covid may present conventionally or atypically.<\/p>\n\n\n\n Typical manifestations include:<\/p>\n\n\n\n But the presentation can be obscured by Long Covid.<\/p>\n\n\n\n A patient may say:<\/p>\n\n\n\n “I am exhausted.”<\/p>\n<\/blockquote>\n\n\n\n That statement could reflect depression, post-exertional malaise, sleep apnea, anemia, autonomic dysfunction, medication effects, endocrine disease, cardiac disease, or several conditions simultaneously.<\/p>\n\n\n\n Similarly:<\/p>\n\n\n\n “I cannot concentrate.”<\/p>\n<\/blockquote>\n\n\n\n could indicate depression, cognitive dysfunction associated with Long Covid, sleep deprivation, medication effects, neurologic disease, or metabolic abnormalities.<\/p>\n\n\n\n Therefore, the clinician must determine what is causing the symptom<\/strong>, not merely document that the symptom exists.<\/p>\n\n\n\n The distinction between anhedonia and fatigue is particularly important.<\/p>\n\n\n\n Fatigue means diminished physical or cognitive energy.<\/p>\n\n\n\n Anhedonia means diminished capacity to experience pleasure or interest.<\/p>\n\n\n\n They frequently coexist but are not synonymous.<\/p>\n\n\n\n A patient with severe Long Covid may be physically incapable of walking around a museum but remain intensely interested in art.<\/p>\n\n\n\n That is not necessarily anhedonia.<\/p>\n\n\n\n Conversely, a patient who has sufficient physical energy but no longer derives pleasure from previously valued activities may have clinically significant anhedonia.<\/p>\n\n\n\n This distinction can be diagnostically decisive.<\/p>\n\n\n\n “Brain fog” is among the most frequently reported symptoms of Long Covid.<\/p>\n\n\n\n It can involve:<\/p>\n\n\n\n Depression can produce many of these symptoms.<\/p>\n\n\n\n The distinction may require longitudinal observation and objective testing.<\/p>\n\n\n\n In Long Covid, cognitive impairment may fluctuate with exertion, sleep, autonomic state, or post-exertional malaise. In depression, cognitive symptoms may be more closely related to mood and motivation.<\/p>\n\n\n\n Again, overlap is common.<\/p>\n\n\n\n A careful history is more valuable than indiscriminate testing.<\/p>\n\n\n\n The clinician should establish:<\/p>\n\n\n\n A negative test should not automatically exclude Long Covid. Current CDC guidance states that laboratory confirmation of previous SARS-CoV-2 infection is not required for diagnosis.<\/p>\n\n\n\n The clinician should ask about:<\/p>\n\n\n\n This is often more informative than symptom counts.<\/p>\n\n\n\n Ask:<\/p>\n\n\n\n Functional decline provides an objective framework for understanding the psychological consequences of Long Covid.<\/p>\n\n\n\n The physical examination should be directed but comprehensive.<\/p>\n\n\n\n Important components include:<\/p>\n\n\n\n Assess:<\/p>\n\n\n\n Evaluate:<\/p>\n\n\n\n Assess:<\/p>\n\n\n\n Document:<\/p>\n\n\n\n Several instruments are useful.<\/p>\n\n\n\n The PHQ-9 is practical for:<\/p>\n\n\n\n It should not be interpreted as a substitute for diagnostic assessment.<\/p>\n\n\n\n Useful when anxiety coexists with depressive symptoms.<\/p>\n\n\n\n Appropriate when suicide risk requires structured assessment.<\/p>\n\n\n\n May be useful when cognitive dysfunction is prominent, although normal performance does not exclude subtle Long Covid cognitive impairment.<\/p>\n\n\n\n Appropriate when hospitalization, intensive care, respiratory failure, bereavement, or traumatic medical experiences are prominent.<\/p>\n\n\n\n The differential diagnosis of depression in Long Covid is broad.<\/p>\n\n\n\n The diagnosis should be considered when the patient has persistent depressed mood or anhedonia accompanied by sufficient additional symptoms, clinically significant distress or impairment, and no better explanation.<\/p>\n\n\n\n Adjustment disorder may better explain depressive symptoms clearly linked to the psychosocial consequences of chronic illness when criteria for major depressive disorder are not met.<\/p>\n\n\n\n Demoralization involves helplessness, hopelessness, loss of meaning, and perceived inability to cope.<\/p>\n\n\n\n It is particularly relevant to chronic disease.<\/p>\n\n\n\n Patients who experienced severe respiratory illness, intensive care, near-death experiences, isolation, or bereavement may develop PTSD.<\/p>\n\n\n\n Before prescribing an antidepressant, clinicians should establish whether there is a history of mania or hypomania.<\/p>\n\n\n\n Potential contributors include certain:<\/p>\n\n\n\n The medication list should be reviewed carefully.<\/p>\n\n\n\n Consider:<\/p>\n\n\n\n Anemia can produce fatigue, reduced exercise tolerance, cognitive symptoms, and low mood.<\/p>\n\n\n\n Depending on the clinical context:<\/p>\n\n\n\n may warrant investigation.<\/p>\n\n\n\n Especially important in patients with obesity, snoring, witnessed apneas, morning headaches, or excessive daytime sleepiness.<\/p>\n\n\n\n Consider:<\/p>\n\n\n\n Alcohol, opioids, sedatives, stimulants, and cannabis may alter mood, cognition, and sleep.<\/p>\n\n\n\n Suicide risk must never be attributed simply to Long Covid.<\/p>\n\n\n\n Nor should it be minimized because the patient has a plausible medical explanation for his or her suffering.<\/p>\n\n\n\n Risk assessment should include:<\/p>\n\n\n\n A patient who expresses imminent suicidal intent requires immediate psychiatric evaluation and protection rather than routine outpatient management.<\/p>\n\n\n\n There is currently no established medication specifically approved as a disease-modifying treatment for Long Covid depression.<\/p>\n\n\n\n This is an important boundary between evidence and hope.<\/p>\n\n\n\n Current CDC guidance emphasizes treatment directed toward the patient’s specific symptoms and conditions, optimization of underlying illnesses, rehabilitation where appropriate, and comprehensive patient-centered care.<\/p>\n\n\n\n WHO similarly states that there are currently no proven drug treatments for post\u2013COVID-19 condition as a whole, although symptomatic treatments and holistic rehabilitation may improve function and quality of life.<\/p>\n\n\n\n Treatment should therefore proceed along two parallel tracks:<\/p>\n\n\n\n Track 1: treat depression according to established psychiatric principles.<\/strong><\/p>\n\n\n\n Track 2: identify and treat the patient’s Long Covid phenotype.<\/strong><\/p>\n\n\n\n Neither track should be neglected.<\/p>\n\n\n\n Psychotherapy is a major component of treatment.<\/p>\n\n\n\n Potential approaches include:<\/p>\n\n\n\n Behavioral activation can be particularly useful because depression tends to produce withdrawal, which further reduces access to rewarding experiences.<\/p>\n\n\n\n However, therapy must be adapted to the physical limitations of Long Covid.<\/p>\n\n\n\n A patient with post-exertional malaise should not be instructed to undertake progressively increasing activity merely because inactivity is considered a behavioral manifestation of depression.<\/p>\n\n\n\n That distinction is critical.<\/p>\n\n\n\n Current Long Covid guidance recognizes post-exertional malaise as a characteristic phenomenon and recommends strategies to mitigate it rather than indiscriminate graded exertion.<\/p>\n\n\n\n Standard antidepressant therapy remains appropriate when the patient meets criteria for a depressive disorder.<\/p>\n\n\n\n Classes include:<\/p>\n\n\n\n Choice should be individualized.<\/p>\n\n\n\n Relevant factors include:<\/p>\n\n\n\n In medically complex patients, “start low and go slow” is often prudent, although this should not become therapeutic inertia.<\/p>\n\n\n\n SSRIs are commonly used because of their efficacy across depressive and anxiety disorders and their relatively favorable safety profile.<\/p>\n\n\n\n However, their use in Long Covid should not be interpreted as evidence that Long Covid depression is caused by serotonin deficiency.<\/p>\n\n\n\n SSRIs may help because antidepressant effects involve complex changes in receptor signaling, neuroplasticity, network function, and stress-response systems.<\/p>\n\n\n\n The clinician should monitor:<\/p>\n\n\n\n Older adults may be particularly vulnerable to hyponatremia.<\/p>\n\n\n\n SNRIs may be useful when depression coexists with:<\/p>\n\n\n\n Their effects on blood pressure and heart rate warrant attention in patients with dysautonomia or cardiovascular disease.<\/p>\n\n\n\n Bupropion may be attractive in selected patients because it is generally less sedating and has a lower propensity for sexual dysfunction.<\/p>\n\n\n\n It may be particularly useful when:<\/p>\n\n\n\n are prominent.<\/p>\n\n\n\n However, seizure risk and other contraindications must be considered.<\/p>\n\n\n\n Mirtazapine may be useful when depression coexists with:<\/p>\n\n\n\n Conversely, sedation and weight gain may be undesirable.<\/p>\n\n\n\n Some patients will not respond adequately to an initial antidepressant.<\/p>\n\n\n\n Treatment-resistant depression requires reassessment before simply adding medications.<\/p>\n\n\n\n The clinician should reconsider:<\/p>\n\n\n\n Augmentation strategies may include selected atypical antipsychotics, lithium, thyroid hormone in selected cases, or other evidence-based interventions.<\/p>\n\n\n\n Electroconvulsive therapy remains one of the most effective treatments for severe depression, particularly when associated with:<\/p>\n\n\n\n Long Covid should not automatically exclude ECT.<\/p>\n\n\n\n The usual medical assessment should, however, be especially careful in patients with:<\/p>\n\n\n\n Transcranial magnetic stimulation is another option for selected patients with treatment-resistant depression.<\/p>\n\n\n\n Its advantages include avoidance of systemic medication exposure and anesthesia.<\/p>\n\n\n\n Whether Long Covid modifies response to TMS is unknown.<\/p>\n\n\n\n Ketamine and intranasal esketamine may be appropriate for selected patients with treatment-resistant depression or acute suicidal risk under established protocols.<\/p>\n\n\n\n Their use specifically for Long Covid\u2013associated depression remains inadequately studied.<\/p>\n\n\n\n The distinction between evidence for depression generally and evidence for Long Covid depression specifically should be maintained.<\/p>\n\n\n\n Sleep treatment may be one of the most effective indirect interventions.<\/p>\n\n\n\n Evaluation should consider:<\/p>\n\n\n\n Cognitive behavioral therapy for insomnia is generally preferred as first-line treatment for chronic insomnia.<\/p>\n\n\n\n Medication should be used selectively, particularly in older adults because sedative medications can increase falls, cognitive impairment, and dependence.<\/p>\n\n\n\n Pain should be treated as an independent therapeutic target.<\/p>\n\n\n\n Potential strategies include:<\/p>\n\n\n\n Pain control may improve mood even when the antidepressant itself has only modest effect.<\/p>\n\n\n\n One of the most important clinical distinctions is between ordinary deconditioning and post-exertional malaise.<\/p>\n\n\n\n PEM can involve delayed worsening after physical or cognitive exertion, commonly beginning hours later and lasting substantially longer than the exertional activity itself. Current CDC guidance specifically describes symptom worsening commonly occurring 12 to 48 hours after exertion and potentially lasting days or weeks.<\/p>\n\n\n\n This has major implications for depression treatment.<\/p>\n\n\n\n A depressed patient may benefit from behavioral activation.<\/p>\n\n\n\n A Long Covid patient with PEM may deteriorate if behavioral activation is implemented as indiscriminate physical exertion.<\/p>\n\n\n\n The therapeutic objective should instead be function without repeated physiologic crashes<\/strong>.<\/p>\n\n\n\n Cognitive rehabilitation may help selected patients with persistent cognitive dysfunction.<\/p>\n\n\n\n Strategies include:<\/p>\n\n\n\n Cognitive symptoms should not automatically be attributed to depression.<\/p>\n\n\n\n Depression and Long Covid can interact to produce profound occupational disability.<\/p>\n\n\n\n A multidisciplinary approach may include:<\/p>\n\n\n\n For many patients, restoring a meaningful role is itself therapeutic.<\/p>\n\n\n\n One of the most consequential interventions may be deceptively simple:<\/p>\n\n\n\n believe the patient.<\/strong><\/p>\n\n\n\n Current CDC guidance specifically recommends validating Long Covid symptoms and recognizing their effects on quality of life and functioning.<\/p>\n\n\n\n Validation does not mean accepting every proposed mechanism.<\/p>\n\n\n\n It means recognizing that the patient’s symptoms are real and clinically meaningful even when routine laboratory tests are normal.<\/p>\n\n\n\n This distinction is particularly important for patients with depression.<\/p>\n\n\n\n The statement:<\/p>\n\n\n\n “Your tests are normal, so nothing is wrong.”<\/p>\n<\/blockquote>\n\n\n\n can deepen hopelessness.<\/p>\n\n\n\n The more scientifically defensible statement is:<\/p>\n\n\n\n “The absence of an abnormal routine test does not establish that your symptoms are imaginary. We need to determine which mechanisms may be contributing and what can be treated.”<\/p>\n<\/blockquote>\n\n\n\n Prognosis is variable.<\/p>\n\n\n\n Some patients improve substantially within months.<\/p>\n\n\n\n Others have persistent symptoms for years.<\/p>\n\n\n\n Still others experience fluctuating disease characterized by periods of improvement followed by relapse.<\/p>\n\n\n\n WHO notes that Long Covid symptoms may persist from the initial illness or develop after apparent recovery and may fluctuate or relapse.<\/p>\n\n\n\n The CDC similarly states that symptoms may last months or years and can emerge, persist, resolve, and reemerge.<\/p>\n\n\n\n The prognosis of depression is likewise variable.<\/p>\n\n\n\n Some depressive episodes resolve with treatment.<\/p>\n\n\n\n Others become recurrent or chronic.<\/p>\n\n\n\n The combination may be particularly difficult because each disorder can sustain the other.<\/p>\n\n\n\n Depression should not necessarily be conceptualized as merely another symptom.<\/p>\n\n\n\n It can function as an amplifier.<\/p>\n\n\n\n Depression may cause:<\/p>\n\n\n\n These effects can worsen Long Covid disability.<\/p>\n\n\n\n At the same time, worsening disability reinforces depression.<\/p>\n\n\n\n The result is a positive feedback loop:<\/p>\n\n\n\n biological illness \u2192 disability \u2192 depression \u2192 reduced function \u2192 greater disability \u2192 deeper depression.<\/strong><\/p>\n\n\n\n Breaking this loop may be more important clinically than determining which component appeared first.<\/p>\n\n\n\n One of the most difficult questions is:<\/p>\n\n\n\n Did Covid cause the depression?<\/strong><\/p>\n\n\n\n The answer will frequently be unknowable.<\/p>\n\n\n\n Temporal association is not proof of causation.<\/p>\n\n\n\n A depressive episode occurring two months after Covid may be related to:<\/p>\n\n\n\n The appropriate clinical response is therefore not to insist upon a single causal narrative.<\/p>\n\n\n\n The clinician should instead identify treatable mechanisms.<\/p>\n\n\n\n Several conclusions are now reasonably well supported.<\/p>\n\n\n\n First, Long Covid is a genuine chronic multisystem condition.<\/p>\n\n\n\n Second, depression and other neuropsychiatric symptoms are common among affected patients.<\/p>\n\n\n\n Third, depression cannot be adequately understood solely as a psychological response to illness.<\/p>\n\n\n\n Fourth, biological mechanisms involving immune, vascular, metabolic, autonomic, and neurologic systems are plausible and supported to varying degrees.<\/p>\n\n\n\n Fifth, no single mechanism explains all Long Covid cases.<\/p>\n\n\n\n Sixth, routine laboratory testing cannot establish or exclude Long Covid.<\/p>\n\n\n\n Seventh, depression should be diagnosed using established psychiatric principles rather than by symptom counting alone.<\/p>\n\n\n\n Eighth, suicidal ideation requires immediate clinical attention irrespective of whether the depressive syndrome is considered secondary to Long Covid.<\/p>\n\n\n\n Ninth, evidence-based psychiatric treatment remains appropriate.<\/p>\n\n\n\n Tenth, management of Long Covid must proceed concurrently rather than waiting for a definitive disease-modifying treatment.<\/p>\n\n\n\n The unanswered questions are equally important.<\/p>\n\n\n\n We do not yet know:<\/p>\n\n\n\n These questions should be priorities for prospective research.<\/p>\n\n\n\n The future of Long Covid psychiatry is unlikely to involve a single diagnosis with a single treatment.<\/p>\n\n\n\n Instead, patients may eventually be classified according to biologically and clinically meaningful phenotypes.<\/p>\n\n\n\n One patient might exhibit:<\/p>\n\n\n\n post-exertional malaise + autonomic dysfunction + cognitive impairment + depression.<\/strong><\/p>\n\n\n\n Another:<\/p>\n\n\n\n persistent pain + sleep disorder + depression.<\/strong><\/p>\n\n\n\n Another:<\/p>\n\n\n\n inflammatory disease + cognitive dysfunction + anxiety\/depression.<\/strong><\/p>\n\n\n\n Another:<\/p>\n\n\n\n post-intensive-care syndrome + PTSD + major depression.<\/strong><\/p>\n\n\n\n Another:<\/p>\n\n\n\n predominantly psychosocial disability + adjustment disorder.<\/strong><\/p>\n\n\n\n Such distinctions could permit more rational treatment.<\/p>\n\n\n\n A practical approach can be summarized in ten steps.<\/p>\n\n\n\n Document the infection and onset of symptoms.<\/p>\n\n\n\n Identify fatigue, PEM, cognitive dysfunction, dysautonomia, pain, sleep abnormalities, respiratory symptoms, cardiovascular disease, and other manifestations.<\/p>\n\n\n\n Determine whether the patient has major depressive disorder, adjustment disorder, demoralization, PTSD, anxiety, bipolar disorder, or another condition.<\/p>\n\n\n\n This should never be omitted.<\/p>\n\n\n\n The diagnosis of Long Covid does not protect the patient from other disease.<\/p>\n\n\n\n Identify medications that may worsen mood, cognition, fatigue, or sleep.<\/p>\n\n\n\n Sleep disorders can mimic or worsen depression.<\/p>\n\n\n\n Use psychotherapy, medication, or advanced treatments as clinically indicated.<\/p>\n\n\n\n Address PEM, autonomic dysfunction, pain, sleep, cognitive impairment, and other specific manifestations.<\/p>\n\n\n\n Repeated assessment is essential because symptoms may evolve.<\/p>\n\n\n\n Future trials should avoid treating Long Covid as a homogeneous condition.<\/p>\n\n\n\n Trials should stratify patients by:<\/p>\n\n\n\n Depression trials should use structured psychiatric diagnoses rather than relying exclusively on symptom questionnaires.<\/p>\n\n\n\n Studies should also distinguish:<\/p>\n\n\n\n depressive symptoms<\/strong><\/p>\n\n\n\n from<\/p>\n\n\n\n major depressive disorder.<\/strong><\/p>\n\n\n\n This seemingly minor distinction is essential.<\/p>\n\n\n\n Long Covid and depression exist in a relationship that is at once biological, psychological, and clinical.<\/p>\n\n\n\n SARS-CoV-2 infection can leave patients with persistent multisystem disease. Among the manifestations are cognitive dysfunction, sleep disturbance, pain, autonomic abnormalities, profound fatigue, and depression. Current evidence indicates that depressive symptoms are common in Long Covid, although prevalence estimates vary markedly among studies because of differences in definitions, populations, instruments, and follow-up.<\/p>\n\n\n\n The biological explanation remains incomplete.<\/p>\n\n\n\n Persistent immune activation, neuroinflammation, endothelial dysfunction, altered tryptophan metabolism, autonomic abnormalities, mitochondrial dysfunction, endocrine disturbance, autoimmunity, and persistent viral antigen have all been proposed. The current evidence supports a pluralistic model rather than a single pathophysiologic theory. The CDC likewise recognizes Long Covid as heterogeneous and identifies several possible underlying mechanisms.<\/p>\n\n\n\n The psychological consequences of chronic illness are equally real.<\/p>\n\n\n\n Loss of mobility, employment, independence, social connection, financial security, and confidence in one’s body can produce legitimate grief and demoralization. Such reactions should neither be pathologized unnecessarily nor used to dismiss biological disease.<\/p>\n\n\n\n The clinician’s task is therefore not to decide whether the patient’s illness is “physical” or “psychological.”<\/p>\n\n\n\n The task is to determine which biological, psychiatric, functional, and social processes are operating simultaneously and which are treatable.<\/strong><\/p>\n\n\n\n Depression should be diagnosed rigorously. Suicide risk should be assessed explicitly. Medical mimics should be excluded. Sleep and pain should be treated. Post-exertional malaise should be recognized. Autonomic dysfunction should not be mislabeled as anxiety. Cognitive impairment should not automatically be attributed to depression. And established psychiatric treatments should not be withheld simply because the depressive illness occurs in the context of Long Covid.<\/p>\n\n\n\n At present, there is no single medication capable of correcting the entire pathophysiology of Long Covid, and there is no proven disease-modifying pharmacologic therapy specifically for Long Covid\u2013associated depression. WHO and CDC guidance accordingly emphasizes individualized, symptom-directed, multidisciplinary care.<\/p>\n\n\n\n The central lesson is therefore one of integration.<\/p>\n\n\n\n Long Covid depression should be understood neither as evidence that Long Covid is primarily psychiatric nor as evidence that psychological factors are irrelevant. It is better understood as a disorder emerging at the intersection of immune biology, neural function, systemic physiology, chronic disability, and human adaptation to prolonged illness.<\/p>\n\n\n\n For the patient, the distinction is not philosophical.<\/p>\n\n\n\n It determines whether the clinician listens.<\/p>\n\n\n\n It determines whether treatable depression is recognized.<\/p>\n\n\n\n It determines whether physical symptoms are dismissed as psychiatric.<\/p>\n\n\n\n And, ultimately, it determines whether the patient is offered a coherent path toward recovery rather than being forced to choose between two incomplete explanations of the same disease.<\/p>\n\n\n\n John Murphy, CEO, The COVID-19 Long-haul Foundation Review Article Abstract Long Covid, or post\u2013COVID-19 condition, has emerged as a heterogeneous, multisystem disorder that may persist for months or years after […]<\/p>\n","protected":false},"author":2,"featured_media":15689,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[113,129,1474,1326,1413,364,537,949],"tags":[],"class_list":["post-15666","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-depression-mental-health","category-dysautonomia","category-endothelial-dysfunction","category-microvascular-damage","category-microvascular-injury","category-neuroinflammation","category-sleep-deprivation","category-sleep-disturbance"],"_links":{"self":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/15666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15666"}],"version-history":[{"count":3,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/15666\/revisions"}],"predecessor-version":[{"id":15669,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/15666\/revisions\/15669"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/media\/15689"}],"wp:attachment":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15666"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15666"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Abstract<\/h5>\n\n\n\n
\n\n\n\nIntroduction<\/h5>\n\n\n\n
\n\n\n\nI. Defining the Clinical Problem<\/h5>\n\n\n\n
Long Covid<\/h5>\n\n\n\n
Depression<\/h5>\n\n\n\n
\n
\n\n\n\nII. The Epidemiology of Depression in Long Covid<\/h5>\n\n\n\n
\n\n\n\nIII. Why Depression May Follow SARS-CoV-2 Infection<\/h5>\n\n\n\n
\n
\n\n\n\nIV. Neuroinflammation<\/h5>\n\n\n\n
\n
\n\n\n\nV. Tryptophan, Kynurenine, and Serotonergic Biology<\/h5>\n\n\n\n
\n\n\n\nVI. Endothelial Dysfunction and Microvascular Disease<\/h5>\n\n\n\n
\n
\n\n\n\nVII. Persistent Viral Antigen and Viral Reservoirs<\/h5>\n\n\n\n
\n
\n\n\n\nVIII. Autoimmunity<\/h5>\n\n\n\n
\n
\n\n\n\nIX. Autonomic Dysfunction<\/h5>\n\n\n\n
\n
\n
\n\n\n\nX. Mitochondrial and Metabolic Dysfunction<\/h5>\n\n\n\n
\n
\n\n\n\nXI. The Hypothalamic\u2013Pituitary\u2013Adrenal Axis<\/h5>\n\n\n\n
\n\n\n\nXII. Sleep: A Major Mediator<\/h5>\n\n\n\n
\n
\n
\n\n\n\nXIII. Pain and Depression<\/h5>\n\n\n\n
\n
\n\n\n\nXIV. The Psychology of Chronic Illness<\/h5>\n\n\n\n
\n
\n\n\n\nXV. Clinical Presentation<\/h5>\n\n\n\n
\n
\n
\n
\n\n\n\nXVI. Anhedonia Versus Fatigue<\/h5>\n\n\n\n
\n\n\n\nXVII. Cognitive Dysfunction Versus Depression<\/h5>\n\n\n\n
\n
\n\n\n\nXVIII. History and Physical Examination<\/h5>\n\n\n\n
History of the SARS-CoV-2 infection<\/h5>\n\n\n\n
\n
Psychiatric history<\/h5>\n\n\n\n
\n
Functional history<\/h5>\n\n\n\n
\n
\n\n\n\nXIX. Physical Examination<\/h5>\n\n\n\n
General examination<\/h5>\n\n\n\n
\n
Cardiovascular examination<\/h5>\n\n\n\n
\n
Neurologic examination<\/h5>\n\n\n\n
\n
Psychiatric examination<\/h5>\n\n\n\n
\n
\n\n\n\nXX. Screening Instruments<\/h5>\n\n\n\n
PHQ-9<\/h5>\n\n\n\n
\n
GAD-7<\/h5>\n\n\n\n
Columbia-Suicide Severity Rating Scale<\/h5>\n\n\n\n
Montreal Cognitive Assessment<\/h5>\n\n\n\n
Post-traumatic stress instruments<\/h5>\n\n\n\n
\n\n\n\nXXI. Differential Diagnosis<\/h5>\n\n\n\n
Major depressive disorder<\/h5>\n\n\n\n
Adjustment disorder<\/h5>\n\n\n\n
Demoralization<\/h5>\n\n\n\n
Post-traumatic stress disorder<\/h5>\n\n\n\n
Bipolar disorder<\/h5>\n\n\n\n
Medication-induced depression<\/h5>\n\n\n\n
\n
Endocrine disease<\/h5>\n\n\n\n
\n
Anemia<\/h5>\n\n\n\n
Vitamin deficiency<\/h5>\n\n\n\n
\n
Sleep apnea<\/h5>\n\n\n\n
Neurologic disease<\/h5>\n\n\n\n
\n
Substance use<\/h5>\n\n\n\n
\n\n\n\nXXII. Suicide Risk<\/h5>\n\n\n\n
\n
\n\n\n\nXXIII. Treatment: General Principles<\/h5>\n\n\n\n
\n\n\n\nXXIV. Psychotherapy<\/h5>\n\n\n\n
\n
\n\n\n\nXXV. Antidepressant Pharmacotherapy<\/h5>\n\n\n\n
\n
\n
\n\n\n\nXXVI. SSRIs<\/h5>\n\n\n\n
\n
\n\n\n\nXXVII. SNRIs<\/h5>\n\n\n\n
\n
\n\n\n\nXXVIII. Bupropion<\/h5>\n\n\n\n
\n
\n\n\n\nXXIX. Mirtazapine<\/h5>\n\n\n\n
\n
\n\n\n\nXXX. Treatment-Resistant Depression<\/h5>\n\n\n\n
\n
\n\n\n\nXXXI. Electroconvulsive Therapy<\/h5>\n\n\n\n
\n
\n
\n\n\n\nXXXII. Transcranial Magnetic Stimulation<\/h5>\n\n\n\n
\n\n\n\nXXXIII. Ketamine and Esketamine<\/h5>\n\n\n\n
\n\n\n\nXXXIV. Treating Sleep<\/h5>\n\n\n\n
\n
\n\n\n\nXXXV. Treating Pain<\/h5>\n\n\n\n
\n
\n\n\n\nXXXVI. Post-Exertional Malaise<\/h5>\n\n\n\n
\n\n\n\nXXXVII. Cognitive Rehabilitation<\/h5>\n\n\n\n
\n
\n\n\n\nXXXVIII. Social and Occupational Rehabilitation<\/h5>\n\n\n\n
\n
\n\n\n\nXXXIX. The Therapeutic Relationship<\/h5>\n\n\n\n
\n
\n
\n\n\n\nXL. Long-Term Prognosis<\/h5>\n\n\n\n
\n\n\n\nXLI. Depression as an Amplifier of Long Covid<\/h5>\n\n\n\n
\n
\n\n\n\nXLII. The Problem of Diagnostic Attribution<\/h5>\n\n\n\n
\n
\n\n\n\nXLIII. What Can Be Said with Confidence<\/h5>\n\n\n\n
\n\n\n\nXLIV. What Remains Uncertain<\/h5>\n\n\n\n
\n
\n\n\n\nXLV. Toward a Phenotype-Based Model<\/h5>\n\n\n\n
\n\n\n\nXLVI. Implications for Clinical Practice<\/h5>\n\n\n\n
1. Establish the temporal relationship<\/h5>\n\n\n\n
2. Characterize the Long Covid phenotype<\/h5>\n\n\n\n
3. Establish the psychiatric phenotype<\/h5>\n\n\n\n
4. Assess suicide risk<\/h5>\n\n\n\n
5. Search for alternative medical causes<\/h5>\n\n\n\n
6. Review medications<\/h5>\n\n\n\n
7. Evaluate sleep<\/h5>\n\n\n\n
8. Treat depression according to evidence-based standards<\/h5>\n\n\n\n
9. Treat the underlying Long Covid phenotype<\/h5>\n\n\n\n
10. Follow longitudinally<\/h5>\n\n\n\n
\n\n\n\nXLVII. Research Priorities<\/h5>\n\n\n\n
\n
\n\n\n\nXLVIII. Conclusion<\/h5>\n\n\n\n
\n\n\n\nReferences and Footnotes<\/h5>\n\n\n\n
\n